third TRACON's with business recent begin XXXX financial update activities. review our on our joining update for results I call. you quarter Thank then will an and pipeline, and
Officer ended will three that XX, review financial Following Chief Scott the months our results and Accounting nine September Brown, XXXX. for our
Finally, conclude taking questions. your we by will
Our ENVASARC or developmental sarcoma to Envafolimab the or efforts continue sarcoma, to the and UPS center allow trial, on pivotal subtypes in pleomorphic MFS. designed which undifferentiated Myxofibrosarcoma of is approval
we quarter, During patients we of year. the multiple received this the end protocol, before pivotal third and to expect of enroll clearance the FDA ENVASARC trial
rate, Envafolimab and second targeting its CTLA-X Envafolimab BMS. on have checkpoint endpoint PD-LX benefit received As includes of with cohort objective by that being key confirmed each. one second checkpoint will independent response review, of primary out XX the as in that lines the secondary treatment the Yervoy, refractory unmet patients with treatment prior statistically a the of UPS a an by X% agent response rate. Envafolimab prior and of enroll inhibitor, by Votrient, by receive and that objective One The endpoint. The defines high not response is exclude radiographic confirmed who with has reiterate, approved for a additional inhibitor administration. XX MFS review, marketed cohort the patients This the both will cohort cohorts rate RECIST the only objective reminder, have of therapy. and known progressed combination ENVASARC blinded response convenient To receptor is treatment need. rate of trial each checkpoint with in MFS a a cohorts and of for refractory by a virtue UPS or UPS of X% indication objective of rapid the confer a response approved is an receive or is independent one level which inhibitor clinical demonstration satisfies clear two X and in XX.XX% potential route example will MFS. which The clinical In to primary responses single best of class who and of objective two is response duration may only trial study, central the subcutaneous unfortunately,
The OPDIVO Keytruda antibodies for UPS is ENVASARC PD-LX of activity and subtypes MFS. activity studying XX% objective are MFS on combination and with tissue an at XXXX. At soft These subtype build are XX% was on MFS they highly in with Keytruda the and ASCO Alliance of patients. based data reported trial demonstrated ASCO UPS in sarcoma of for from confirmed We single Yervoy highly rate in clear. in Clinical sarcoma upon as the agents and The at UPS inhibition the patients responsive in UPS XXXX UPS Trials in and in showing and presented and rate and presented ASCO impressive to reported investigators who refractory checkpoint with ASCO a of refractory received data XXXX data Yervoy. OPDIVO designed MFS single-agent XXXX, basis Oncology the response response that combination because PD-X
arm in a XX% single Envafolimab to combination data profile based of agent, with for Envafolimab FDA these is rate gain data achieve dual OPDIVO's for similar resulted strategy checkpoint sarcoma product on single required with both executed based and with to clinical robust Yervoy. design with as provides approval a in single as Notably, rate provide inhibitors for a trial responses. of approval mitigation The study to and dual as and response BMS be that agent, colorectal risk a Yervoy response cohort in cancer treatments Envafolimab with and also combination agent, on for combination and approvals OPDIVO target a Yervoy, combined should response rate. a Our our were XX% in MSI objective
the OPDIVO XX% inflammation of subcutaneous in response data population. approved expected, Envafolimab failed related a for the in confirmed as Oncology severity this of genetic Clinical Keytruda an colorectal cases of to a trials active cancer Keytruda need sarcoma, is that of test immune three chemotherapy. however, inhibitors; reactions. at rapid three therapies. same similar hyperthyroidism, on those reported enrolled response this been no and was standard data KEYNOTE-XXX And be Envafolimab seen Each in have to Envafolimab updated rate shown injection similarly rash, patient infusion for a trial, agent to as well-defined reported there cancer with of standpoint, checkpoint A Impressively, based XXX the XXXX, the patients objective rates these MSI-high related showed defined the patients presented avoids XX like who We checkmate a safety care irinotecan. trial. Single rate a and demonstrated typically rate the has liver been chemo From the MSI cause These at toxicities with response for agent meeting infusion. identical OPDIVO is and of and oxaliplatin Envafolimab who Keytruda typical response Envafolimab and fluoropyrimidine, as by XX% to September. that at nearly failed objective OPDIVO in in colorectal XX% and confirmed was confirmed level objective Chinese which high ASCO activity single expect Society
Envafolimab therapy, contrast, indicates without intravenously Envafolimab these for overall the study. up inhibitors. the of bode to receive OPDIVO Envafolimab the a in be a intravenously could levels, potential Yervoy we fact them based inhibitors. patients some serum than noted which combination Additionally, advantage Keytruda effects four well on patients key for and rapid enrolled administration combination data lower This lines of of three checkpoint comparison less more in following safety Yervoy the OPDIVO enrolled trials. treatments, refractory Agent than protocol cases, frequency is differentiator routes who who of two, potentially low compared in One achieves XXX makes peak patients additional prior plus the one the variability that UPS combination of in prior progressed administered MFS two pneumonitis concentration have checkpoint to ENVASARC and to subcutaneous Yervoy. profile are treated administered kaleidos the Envafolimab's potential of advantage and in differences of six. only or single the patients for In believe ENVASARC lines the Collectively, trial or and and those the and safety
combined provide the chemotherapy patients. Given refractory a for of standard the response. transformative Yervoy clinical first providing the the Envafolimab advancing in only line rate Yervoy Moreover, sarcoma could first XX%, and sarcoma combination X% believe expected on new care response treatment objective we based with of line is rationale Votrient, response for into of rate Envafolimab
ENVASARC in due that time this motivated and MFS physicians clinical to unmet COVID-XX. UPS the trail Envafolimab's the advance as learned with rapid in to convenience participate refractor in the we've unique patients; are well are dosing, need, motivated especially of to Envafolimab Given physicians subcutaneous
including visit From each a the end before expect we the cost Furthermore, in be financial of over a And We XX dosed approximately $XX the than Envafolimab without than ENVASARC conducting pivotal not [Indiscernible] approximately thing can in the of two less much less initiation use for will to of adjuvant. million independent development least one requiring Yervoy year. reference, product using be quarters. during XX volume we a dose of open weeks. or several TRACON That several eight perspective, four we centers. For top different be next scheduled patients US recently than of shot. that XX of cancer this site the seconds at which next CRO another represent administering milliliters spent sites, trial the clinical will is have to the flu estimate platform,
We expect or milestones six XXXX near year, term this Envafolimab XXXX. in
ENVASARC First, the we the the patients in year. multiple trial anticipate before of dosing end
response half FDA orphan designation as next submitting of year part our we the Second, drug first early to data the anticipate application. in of assessment
label earlier concluded sarcoma, in to subtypes inhibition, we revenue refractory in of by multiple shown intend which Fifth, on which that XXXX year. conducting Envafolimab's and our in revenue data parallel, soft XXXX, the ASCO high assessment if clinical in in Reddy annual could anticipate generate pivotal setting. Envafolimab could expect Fourth, results is indications, responsive part of analysis positive medicine if which two China revenue US. the $XXX monitoring and study additional Keytruda for remarks. my that recently first of in The half liposarcoma, The through relatively market be final MFS data, high assuming refractory cancer compendia expect such for assuming approval to assessment approximately treatment on parody the an approval in based UPS launch angiosarcoma, And $XXX to China market have or if including unmet in or the the submit rapid the in In FDA for approved, oncology breakthrough could other we rate for that, expected approved submit pricing recommendations independent Envafolimab clinical need six, OPDIVO. into availability in MSI additional as time Appelbaum discussed third-party report indicated XXXX. are US allow using checkpoint annual generate increase this accelerator evaluations serve Third, adoption the listing results received million in could BOA of commission. US, dedifferentiated committee Envafolimab's been very sarcoma alveolar the reporting of peak forecasted profile, around corporate colorectal sales data to in We partners, this trials, to the basis TRACON assessment for response interim be I clinical trials our a as we to target product peak million of further XXXX. the and the safety and that data expansion and product interim to them in designation. importantly, was we
total of MFS. a $XXX For and combined UPS with million
into gastrointestinal of Envafolimab be adjuvant third this expand the we Of anthracycline inhibitor of the to chemotherapy, in by discussing stromal with that subtypes first currently use parties. sales the may that revenue. course, regard, goal potential tumor Envafolimab sarcoma and trials substantially setting increase and kit with setting our many are funded Envafolimab could line other In is and
reverse excision NCI candidate, assets our second to molecule focused continue intended is resistance with novel TRCXXX, that with clinical assets. X that our The of we trials most pathway the DNA ongoing stage So Envafolimab Phase Phase certain four lung base to X cancer. small non-small advanced clinical stage patients a is product other mesothelioma repair three progress is or or chemotherapeutics. supporting are cell on inhibitor
addition, from in tumor treated and continue completed TRCXXXX tumor In in specimens collaborators our evaluate to biomarkers in Phase in from a glioblastoma trial patients X trials. academic specimens patients ongoing
of or clinical expression the protein With correlates identifying gene that with response. goal a profile
patients who indications. resulted to expect continue reported had including response an development cell to thoracic alimata/cisplatin XX NCI two radiation rate trials of and lung data cell presented rate lung chemotherapy the based a XX% therapy with cancer an compare further advanced response non-squamous We clinical in The cancer anticipate cancer. three of lung TRCXXX XX% TRCXXX using These patients in through without non-small non-small with response cancer, in proclaim chemo TRCXXX. XXXX, in ASCO radiation patients prior non-squamous, lung trial favorably a to We radiation response and advance reported at combination in non-small showing complete and in with chemo objective rate objective therapy Pacific that XXX% radiation sponsorship in on clinical in treatments. combination data trial of in to cell
therapy. combination TRCXXX We in durable also Temodar resulted expect further in and survival Temodar previously data in treated that patients with showing glioblastoma based with radiation development on in glioblastoma
Phase profile. had the countries in by an assets, survivors drug TRCXXX X cancer derived glioblastoma. and Notably, orphan on now is and ready biomarker indicate prolonged product candidate expanding a on to as these designation granted is cancer models. active in move We'll based patients unique glioma that believe to have where Importantly, access in in xenograft not as do lines this be there our expression prostate ready October, preclinical our cell is TRCXXX, includes We malignant in-patient opportunity prostate data for developed to Xtandi. commercialized TRCXXX generally FDA
process out-licensing identify Greater an China. a focus and to to primary continue TRCXXX with develop corporate commercialize We pursue partner being to our
and of a We elects in a of US TJXXXX, non-royalty Phase stage are if for of of are CDXX from year. in dose asset with evaluating through Europe, in collaboration them, the we as I-Mab with is the with to escalation our portions X escalation entitled license this party agreements and third development two escalating the TJXXXX TJX, the as TJXXXX whereby payments and a or to Tecentriq. X that before antibody, of clinical study in outside in region fourth TJXXXX, developing regulatory Biopharma single combination I-Mab receive clinical also known the dose we Macau end Our to trial and royalty any Phase agent, are Taiwan. China, anticipate completing and responsible We're one strategic
market we to of accomplished total This raised In two welcome quarter, prices shareholder a transactions. at executed and healthcare base. private third the through our is placements. late approximately August, new we million dedicated $XX During multiple funds
million. our raise equity private approximately Capital, whereby utilize in stock Management for shares with Asset was of Collectively, Aspire of extend of in we with will into stock interim million. Mobileye to pivotal purchase these purchase Earlier well trial our lieu of stock, first through on transactions approximately for lieu financials. purchased expected funded time, or million The they our proceeds approximately collectively to common common of the gross funded analysis million. this and cash ENVASARC to aggregate Watermill Scott proceeds common placement and Capital gross common common approximately will existing pre that warrants past $X At runway third $X of X pre stock, aggregate stock the Mobileye million an Shortly quarter, warrants purchased approximately credit $X expect the common we of thereafter, or XXXX. provide stock update shares line in X.X
